우수사례 | Best Practice and Cases in Lottery and Gambling | 最佳实践
- date : 2015-05-20 01:10|hit : 13194
-
- Article] RELATIONSHIP BETWEEN SCHEDULE-INDUCED-POLYDIPSIA AND AMPHETAMINE INTRAVENOUS SELF-ADMINISTRATION - INDIVIDUAL-DIFFERENCES AND ROLE OF EXPERIENCE
-
DocNo of ILP: 8241
Doc. Type: Article
Title: RELATIONSHIP BETWEEN SCHEDULE-INDUCED-POLYDIPSIA AND AMPHETAMINE INTRAVENOUS SELF-ADMINISTRATION - INDIVIDUAL-DIFFERENCES AND ROLE OF EXPERIENCE
Authors: PIAZZA, PV; MITTLEMAN, G; DEMINIERE, JM; LEMOAL, M; SIMON, H
Full Name of Authors: PIAZZA, PV; MITTLEMAN, G; DEMINIERE, JM; LEMOAL, M; SIMON, H
Keywords by Author: ADDICTION; COPING; INDIVIDUAL DIFFERENCE; SCHEDULE-INDUCED POLYDIPSIA; INTRAVENOUS SELF-ADMINISTRATION; AMPHETAMINE
Keywords Plus: PITUITARY-ADRENAL ACTIVITY; NUCLEUS-ACCUMBENS; INGESTIVE BEHAVIOR; 6-HYDROXYDOPAMINE LESIONS; CORTICOSTERONE LEVELS; ADJUNCTIVE BEHAVIOR; COCAINE; RATS; VULNERABILITY; ADDICTION
Abstract: It has been suggested that drug abuse belongs to a larger class of addictive behaviors, including smoking, eating or gambling, which are mediated by common processes. Since laboratory animals can be induced to develop drug self-administration as well as indulge in compulsive eating or drinking, the present experiments were designed to find out if the same animals were susceptible to both behaviors. Only certain rats develop amphetamine intravenous self-administration (SA), and this susceptibility can be predicted from their enhanced locomotor response in a novel environment. Furthermore, excessive, non-regulatory drinking, referred to as schedule-induced polydipsia (SIP), in response to the periodic delivery of small amounts of food is only observed in certain rats. Since the propensity to SA has been shown to be influenced by experimental factors and testing for SIP was found to modify behavioral and biological parameters related to the propensity for drug-seeking, we also investigated whether experience of SIP influenced the subsequent development of SA. In Expt. 1, the rats that developed SA also acquired SIP, and had a higher locomotor response to novelty. The results of Expt. 2 showed that testing for SIP influenced the predisposition to develop amphetamine SA. When animals were tested for SIP first, the polydipsic rats subsequently failed to acquire SA, and had a reduced locomotor response to novelty. These changes seemed to be specific to the experience of SIP, as individual differences in the locomotor response to novelty were unchanged when animals were housed in standard laboratory conditions over a period of one month between the two tests. First and foremost, the results indicate that the predisposition to develop amphetamine SA is related to other behaviors with compulsive features, such as SIP. Secondly, these results demonstrate the powerful influence of a specific experience that is thought to have a coping function, in reducing or altering vulnerability to addiction.
Cate of OECD: Psychology
Year of Publication: 1993
Business Area: gamble
Detail Business: gamble
Country: Netherlands
Study Area:
Name of Journal: BEHAVIOURAL BRAIN RESEARCH
Language: English
Country of Authors:
Press Adress: PIAZZA, PV (reprint author), UNIV BORDEAUX 2,PSYCHOBIOL COMPORTEMENTS ADAPTATIFS,INSERM,U259,DOMAINE CARREIRE,F-33077 BORDEAUX,FRANCE.
Email Address:
Citaion:
Funding:
Lists of Citation: ABRAMS DB, 1983, STRESS ALCOHOL USE, P54; ANTELMAN SM, 1976, PHYSIOL BEHAV, V17, P743, DOI 10.1016/0031-9384(76)90033-0; BARRETT JE, 1986, BEHAV ANAL DRUG DEPE, P195; BEECH HR, 1974, OBSESSIONAL STATES, P3; BRETT LP, 1979, J COMP PHYSIOL PSYCH, V93, P946, DOI 10.1037/h0077619; Costall B., 1977, COCAINE OTHER STIMUL, P47; CREESE I, 1975, BRAIN RES, V83, P419, DOI 10.1016/0006-8993(75)90834-3; DANTZER R, 1988, PHYSIOL BEHAV, V43, P269, DOI 10.1016/0031-9384(88)90186-2; DANTZER R, 1988, PHYSIOL BEHAV, V43, P275, DOI 10.1016/0031-9384(88)90187-4; DEMINIERE JM, 1989, NEUROSCI BIOBEHAV R, V13, P141, DOI 10.1016/S0149-7634(89)80023-5; DEWIT H, 1986, DRUG ALCOHOL DEPEN, V16, P314; Donovan D. M., 1988, ASSESSMENT ADDICTIVE, P3; EVERETT PB, 1970, PSYCHON SCI, V18, P278; FALK JL, 1961, SCIENCE, V133, P195, DOI 10.1126/science.133.3447.195; FALK JL, 1991, J PHARMACOL EXP THER, V257, P457; FALK JL, 1977, ANIM LEARN BEHAV, V5, P325, DOI 10.3758/BF03209574; FALK JL, 1971, PHYSIOL BEHAV, V6, P577, DOI 10.1016/0031-9384(71)90209-5; HOOKS MS, 1992, PHARMACOL BIOCHEM BE, V41, P203, DOI 10.1016/0091-3057(92)90083-R; HOOKS MS, 1991, SYNAPSE, V9, P121, DOI 10.1002/syn.890090206; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; KHANTZIAN EJ, 1984, PSYCHIAT ANN, V14, P753; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LEMOAL M, 1979, NATURE, V280, P156; LEVENTHAL H, 1980, PSYCHOL BULL, V88, P370, DOI 10.1037/0033-2909.88.2.370; LEVINE R, 1989, BEHAV NEUROSCI, V103, P621, DOI 10.1037//0735-7044.103.3.621; LYNESS WWH, 1979, PHARM BIOHC BEHAV, V11, P231; MACLENNAN AJ, 1983, SCIENCE, V219, P1091, DOI 10.1126/science.6681679; Milkman H, 1980, NIDA Res Monogr, V30, P38; MITTLEMAN G, 1984, SCIENCE, V224, P415, DOI 10.1126/science.6710151; MITTLEMAN G, 1988, BEHAV BRAIN RES, V28, P315, DOI 10.1016/0166-4328(88)90134-9; MITTLEMAN G, 1985, BRAIN RES, V348, P112, DOI 10.1016/0006-8993(85)90366-X; MITTLEMAN G, 1986, BEHAV NEUROSCI, V100, P213, DOI 10.1037/0735-7044.100.2.213; MITTLEMAN G, 1990, BEHAV NEUROSCI, V104, P39; O'Brien C. P., 1986, BEHAV ANAL DRUG DEPE, P329; Piazza P. V., 1990, BEHAV PHARMACOL, V1, P339; PIAZZA PV, 1989, SCIENCE, V245, P1511, DOI 10.1126/science.2781295; PIAZZA PV, 1991, BRAIN RES, V567, P169, DOI 10.1016/0006-8993(91)91452-7; PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A; PIAZZA PV, 1991, P NATL ACAD SCI USA, V88, P2088, DOI 10.1073/pnas.88.6.2088; PLOMIN R, 1989, NATURE NURTURE INFAN, P6; PULVIRENTI L, 1991, MESOLIMBIC DOPAMINE SYSTEM : FROM MOTIVATION TO ACTION, P131; ROBBINS TW, 1980, NATURE, V285, P409, DOI 10.1038/285409a0; ROBBINS TW, 1982, INT REV NEUROBIOL, V23, P303, DOI 10.1016/S0074-7742(08)60628-5; ROBERTS DCS, 1982, PHARMACOL BIOCHEM BE, V17, P901, DOI 10.1016/0091-3057(82)90469-5; ROBERTS DCS, 1980, PHARMACOL BIOCHEM BE, V12, P781, DOI 10.1016/0091-3057(80)90166-5; ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0; ROUGEPONT F, 1993, BRAIN RES, V602, P169, DOI 10.1016/0006-8993(93)90260-T; SCHENK S, 1987, NEUROSCI LETT, V81, P227; SCHUSTER CR, 1969, ANNU REV PHARMACOLOG, V9, P483, DOI 10.1146/annurev.pa.09.040169.002411; Shiffman S., 1985, COPING SUBSTANCE USE; SINGER G, 1982, NEUROSCI BIOBEHAV R, V6, P77, DOI 10.1016/0149-7634(82)90008-2; TANG M, 1990, DRUG ALCOHOL DEPEN, V25, P21, DOI 10.1016/0376-8716(90)90135-2; TAZI A, 1988, BRAIN RES, V445, P211, DOI 10.1016/0006-8993(88)91180-8; TAZI A, 1986, BEHAV BRAIN RES, V19, P249, DOI 10.1016/0166-4328(86)90025-2; WALKER VJ, 1969, BRIT J PSYCHIAT, V115, P1261, DOI 10.1192/bjp.115.528.1261; WEEKS JR, 1962, SCIENCE, V138, P143, DOI 10.1126/science.138.3537.143; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469
Number of Citaion: 58
Publication: ELSEVIER SCIENCE BV
City of Publication: AMSTERDAM
Address of Publication: PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
ISSN: 0166-4328
29-Character Source Abbreviation: BEHAV BRAIN RES
ISO Source Abbreviation: Behav. Brain Res.
Volume: 55
Version: 2
Start of File: 185
End of File: 193
DOI: 10.1016/0166-4328(93)90114-6
Number of Pages: 9
Web of Science Category: Behavioral Sciences; Neurosciences
Subject Category: Behavioral Sciences; Neurosciences & Neurology
Document Delivery Number: LM503
Unique Article Identifier: WOS:A1993LM50300008
[이 게시물은 HyeJung Mo…님에 의해 2015-05-20 20:27:31 GAMBLING에서 이동 됨]
- reply : 0
-
- list
-
- next